The National Health Service (NHS) in the UK is set to implement the most significant expansion of its childhood immunisation programme in a decade, introducing a universal chickenpox vaccine for all babies starting next year. This landmark move, announced today, aims to make chickenpox a "problem of the past," with experts hailing it as a "life saver." Ministers have also emphasized the vaccine's broader societal benefits, projecting savings of millions of sick days from schools and nurseries and alleviating the burden on parents who often scramble for childcare or miss work due to the highly contagious illness.

Often perceived as a mild childhood rite of passage, chickenpox, caused by the varicella-zoster virus, is far more serious than commonly understood. It is exceptionally contagious, with each infected individual capable of passing the virus on to approximately ten others, significantly higher than the common cold or flu. While most children recover, the illness can lead to severe complications, including pneumonia, brain inflammation (encephalitis), and dangerous bacterial infections. In rare instances, these complications can be fatal, with an average of 25 deaths annually and hundreds of babies hospitalised in England due to severe symptoms. Chickenpox also poses significant risks during pregnancy, impacting both mother and baby. Common symptoms include an itchy, spotty rash, high temperature, aches, and loss of appetite, necessitating isolation until all spots have scabbed over, typically around five days.

From January, the chickenpox vaccine, also known as the varicella vaccine, will be combined with the existing measles, mumps, and rubella (MMR) vaccine to form a new MMRV jab, effectively replacing the standalone MMR. This live vaccine contains a weakened version of the chickenpox virus, meaning it is not recommended for individuals with compromised immune systems due to conditions like HIV or treatments such as chemotherapy. This strategic shift brings the UK in line with other developed nations, including Germany, Canada, Australia, and the United States, which already incorporate routine varicella vaccination into their childhood schedules.

The vaccine boasts an impressive 98 percent effectiveness, with nine out of ten children developing immunity after a single dose, and even higher protection achieved with both doses. While the NHS notes that protection may wane over time for vaccinated teenagers and adults, making approximately three-quarters immune, the jab significantly reduces the risk of developing chickenpox or experiencing a severe case. In contrast, natural infection typically grants almost all children long-lasting immunity. Experts have consistently affirmed the vaccine's safety, citing mild and short-lasting common side effects such as a sore arm, a mild rash, and a high temperature, comparable to other routine vaccines. Serious side effects, like allergic reactions, are exceedingly rare, occurring in about one in a million people. Although the MMRV jabs, manufactured by Merck & Co, carry a very small increased risk of seizures (estimated at one additional seizure per 2,300 doses), the Joint Committee on Vaccination and Immunisation (JCVI) has deemed this not to be of clinical concern. Decades of use in countries like the US, which has offered the vaccine since 1995, have yielded no evidence of increased health risks, and these nations have reported significant reductions in chickenpox cases and hospitalisations.

The delay in the UK's universal rollout was previously due to concerns that childhood vaccination might lead to a problematic rise in shingles, a painful condition also caused by the varicella-zoster virus, or result in more severe chickenpox cases in adulthood. However, this theory has been repeatedly disproved by robust evidence. Health officials changed their position in 2023, with the JCVI recommending the jab for children after the latest scientific data clearly indicated that the benefits of vaccination substantially outweighed any perceived risks.

The new programme will target more than half a million children each year, offering two doses at 12 months and 18 months of age. While a catch-up programme for millions of under-fives is currently under consideration, the chickenpox vaccine is not expected to be made available to older children through the NHS. This new schedule also adjusts the timing of the second MMR dose, moving it from three years and four months to 18 months for babies born from July last year onwards. Currently, chickenpox vaccination on the NHS is limited to specific groups, such as children and adults in close contact with immunocompromised individuals, while private clinics and pharmacies offer the jab at an approximate cost of £150. Beyond chickenpox, a separate shingles vaccine is already available on the NHS for eligible adults aged 65-79 and those over 50 with severely weakened immune systems.

The economic ramifications of chickenpox are substantial; the illness costs the UK an estimated £24 million annually in lost income and productivity due to parental absences from work. The rollout of the vaccine is anticipated to save the NHS a further £15 million each year in treatment costs, reinforcing the government's commitment to preventive healthcare. Health Minister Stephen Kinnock expressed his delight, stating that the "groundbreaking chickenpox vaccine" will help raise "the healthiest generation of children ever" and provide parents with peace of mind.

Despite the promising prospects of the new vaccine, the NHS faces an ongoing battle to increase overall childhood jab uptake. Recent data has revealed a concerning trend: none of the routine childhood vaccines in England met the 95 percent uptake target in 2024/25. Specifically, uptake of the first MMR dose among five-year-olds fell below 92 percent, marking the lowest level in over a decade, and among two-year-olds, it stood at approximately 89 percent, the lowest since 2009/10. These figures underscore the challenge of ensuring broad public health protection, even as the immunisation schedule evolves to include critical new protections like the varicella vaccine.